Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

Desjeux, 1992, Human leishmaniases: epidemiology and public health aspects, World Health Stat Q, 45, 267

Desjeux, 1996, Leishmaniasis. Public health aspects and control, Clin Dermatol, 14, 417, 10.1016/0738-081X(96)00057-0

2001

Thakur, 2000, Socio-economics of visceral leishmaniasis in Bihar (India), Trans R Soc Trop Med Hyg, 94, 156, 10.1016/S0035-9203(00)90255-4

Arias, 1996, The re-emergence of visceral leishmaniasis in Brazil, Emerg Infect Dis, 2, 145, 10.3201/eid0202.960213

Seaman, 1996, The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994, Int J Epidemiol, 25, 862, 10.1093/ije/25.4.862

Herwaldt, 1999, Leishmaniasis, Lancet, 354, 1191, 10.1016/S0140-6736(98)10178-2

Ho, 1982, Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya, Trans R Soc Trop Med Hyg, 76, 741, 10.1016/0035-9203(82)90095-5

Cerf, 1987, Malnutrition as a risk factor for severe visceral leishmaniasis, J Infect Dis, 156, 1030, 10.1093/infdis/156.6.1030

Alvar, 1997, Leishmania and human immunodeficiency virus coinfection: the first 10 years, Clin Microbiol Rev, 10, 298, 10.1128/CMR.10.2.298

Berman, 1997, Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years, Clin Infect Dis, 24, 684, 10.1093/clind/24.4.684

Desjeux, 1998

Pintado, 2001, HIV-associated visceral leishmaniasis, Clin Microbiol Infect, 7, 291, 10.1046/j.1198-743x.2001.00262.x

Wijeyaratne, 1994, Endemic disease and development: the leishmaniases, Acta Trop, 56, 349, 10.1016/0001-706X(94)90106-6

Murray, 1994, The global burden of disease in 1990: summary results, sensitivity analysis and future directions, Bull World Health Organ, 72, 495

Saxena, 1996, Visceral leishmaniasis control in India through primary health care system: a successful experiment of district level planning, J Commun Dis, 28, 122

Bora, 1999, Epidemiology of visceral leishmaniasis in India, Natl Med J India, 12, 62

Gramiccia, 1992, Decreased sensitivity to meglumine antimoniate (Glucantime) of leishmania infantum isolated from dogs after several courses of drug treatment, Ann Trop Med Parasitol, 86, 613, 10.1080/00034983.1992.11812717

Tayeh, 1997

Elnaiem, 1999, Protective efficacy of lambdacyhalothrin-impregnated bednets against Phlebotomus orientalis, the vector of visceral leishmaniasis in Sudan, Med Vet Entomol, 13, 310, 10.1046/j.1365-2915.1999.00191.x

Vythilingam, 1999, Laboratory evaluation of lambda-cyhalothrin a microencapsulated formulation on mosquito nets for control of vector mosquitos, Southeast Asian J Trop Med Public Health, 30, 177

Khalil, 2000, Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan, Lancet, 356, 1565, 10.1016/S0140-6736(00)03128-7

Herwaldt, 1999, Leishmaniasis, 1189

Boelaert, 1999, Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis, Bull World Health Organ, 77, 667

Boelaert, 1999, Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis, Trop Med Int Health, 4, 31, 10.1046/j.1365-3156.1999.00348.x

Sundar, 1998, Rapid accurate field diagnosis of Indian visceral leishmaniasis, Lancet, 351, 563, 10.1016/S0140-6736(97)04350-X

Salotra, 2001, Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala- azar dermal leishmaniasis, J Clin Microbiol, 39, 849, 10.1128/JCM.39.3.849-854.2001

Cascio, 2002, Polymerase chain reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children, Pediatrics, 109, E27, 10.1542/peds.109.2.e27

Pizzuto, 2001, Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1, J Clin Microbiol, 39, 357, 10.1128/JCM.39.1.357-361.2001

Sundar, 1991, Diagnostic lag period in kala-azar: test for early diagnosis needed, J Assoc Phys India, 39, 651

Schmidt, 1938

Sundar, 2000, Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic, Clin Infect Dis, 31, 1104, 10.1086/318121

Chulay, 1985, Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate), Am J Trop Med Hyg, 34, 702, 10.4269/ajtmh.1985.34.702

Sundar, 1998, A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate, Am J Trop Med Hyg, 59, 139, 10.4269/ajtmh.1998.59.139

Moore, 2001, Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya, Bull World Health Organ, 79, 388

Ritmeijer, 2001, Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome, Trans R Soc Trop Med Hyg, 95, 668, 10.1016/S0035-9203(01)90110-5

Veeken, 2000, A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan, Trop Med Int Health, 5, 312, 10.1046/j.1365-3156.2000.00555.x

Murray, 2001, Clinical and experimental advances in treatment of visceral leishmaniasis, Antimicrob Ag Chemother, 45, 2185, 10.1128/AAC.45.8.2185-2197.2001

Bryceson, 2001, Current issues in the treatment of visceral leishmaniasis, Med Microbiol Immunol (Berl), 190, 81, 10.1007/s004300100086

Sundar, 2001, Drug resistance in Indian visceral leishmaniasis, Trop Med Int Health, 6, 849, 10.1046/j.1365-3156.2001.00778.x

Lira, 1999, Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani, J Infect Dis, 180, 564, 10.1086/314896

Davidson, 1998, Practical guide for the treatment of leishmaniasis, Drugs, 56, 1009, 10.2165/00003495-199856060-00005

Bryceson, 1985, Visceral leishmaniasis unresponsive to antimonial drugs: I, clinical and immunological studies, Trans R Soc Trop Med Hyg, 79, 700, 10.1016/0035-9203(85)90197-X

Ben Salah, 2000, Investigation of the spread of human visceral leishmaniasis in central Tunisia, Trans R Soc Trop Med Hyg, 94, 382, 10.1016/S0035-9203(00)90112-3

Thakur, 1996, Comparison of regimens of amphotericin B deoxycholate in kala-azar, Indian J Med Res, 103, 259

Berman, 1998, Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries, Bull World Health Organ, 76, 25

Davidson, 1994, Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial, QJM, 87, 75

Sundar, 2001, Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial, BMJ, 323, 419, 10.1136/bmj.323.7310.419

Sundar, 1999, Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis, J Assoc Phys India, 47, 186

Berman, 1999, Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion, Chemotherapy, 45, 54, 10.1159/000048471

Laguna, 1999, Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B, AIDS, 13, 1063, 10.1097/00002030-199906180-00009

Russo, 1996, Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome), J Infect, 32, 133, 10.1016/S0163-4453(96)91343-2

De La Rosa, 2001, Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients, Clin Infect Dis, 32, 633, 10.1086/318708

Olliaro, 2002, Developments in the treatment of leishmaniasis and trypanosomiasis, Expert Opin Emerging Drugs, 7, 61, 10.1517/14728214.7.1.61

Wirth, 2002, A harvest not yet reaped: genomics to new drugs in leishmania and trypanosomes, 33

Trouiller, 2002, Drug development for neglected diseases: a deficient market and a public-health policy failure, Lancet, 359, 2188, 10.1016/S0140-6736(02)09096-7

Sundar, 1998, Trial of oral miltefosine for visceral leishmaniasis, Lancet, 352, 1821, 10.1016/S0140-6736(98)04367-0

Sundar, 1999, Oral treatment of visceral leishmaniasis with miltefosine, Ann Trop Med Parasitol, 93, 589, 10.1080/00034989958096

Jha, 1999, Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis, N Engl J Med, 341, 1795, 10.1056/NEJM199912093412403

Bryceson, 2001, A policy for leishmaniasis with respect to the prevention and control of drug resistance, Trop Med Int Health, 6, 928, 10.1046/j.1365-3156.2001.00795.x

Thakur, 2000, Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine): an open-label randomized phase-II clinical study, Trans R Soc Trop Med Hyg, 94, 432, 10.1016/S0035-9203(00)90131-7

Jha, 1998, Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India, BMJ, 316, 1200, 10.1136/bmj.316.7139.1200

Seaman, 1996, Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources, Ann Intern Med, 124, 664, 10.7326/0003-4819-124-7-199604010-00007

Scott, 1992, Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom, Trans R Soc Trop Med Hyg, 86, 617, 10.1016/0035-9203(92)90151-2

Thakur, 1992, Treatment of visceral leishmaniasis (kala-azar) with aminosidine (paromomycin)-antimonial combinations, a pilot study in Bihar, India, Trans R Soc Trop Med Hyg, 86, 615, 10.1016/0035-9203(92)90150-B

Thakur, 1995, Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial, Trans R Soc Trop Med Hyg, 89, 219, 10.1016/0035-9203(95)90503-0

Thakur, 2000, A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis, Trans R Soc Trop Med Hyg, 94, 429, 10.1016/S0035-9203(00)90130-5

Sherwood, 1994, Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis, Clin Infect Dis, 19, 1034, 10.1093/clinids/19.6.1034

Dietze, 2001, Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi, Am J Trop Med Hyg, 65, 685, 10.4269/ajtmh.2001.65.685

Boelaert, 1999, Diagnostic PCR with Leishmania donovani specificity, Trop Med Int Health, 4, 789, 10.1046/j.1365-3156.1999.00487.x

Boelaert, 1999, Operational validation of the direct agglutination test for diagnosis of visceral leishmaniasis, Am J Trop Med Hyg, 60, 129, 10.4269/ajtmh.1999.60.129

Boelaert, 1999, Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis, Trop Med Int Health, 4, 31, 10.1046/j.1365-3156.1999.00348.x

Jha, 1996, Direct agglutination test for early diagnosis of Indian visceral leishmaniasis, J Assoc Phys India, 44, 606

Oskam, 1999, Evaluation of the direct agglutination test (DAT) using freeze-dried antigen for the detection of anti-Leishmania antibodies in stored sera from various patient groups in Ethiopia, Trans R Soc Trop Med Hyg, 93, 275, 10.1016/S0035-9203(99)90021-4

Zijlstra, 2001, Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan, Trop Med Int Health, 6, 108, 10.1046/j.1365-3156.2001.00680.x

de, 1995, Short report: detection of 72-75-kD and 123-kD fractions of Leishmania antigen in urine of patients with visceral leishmaniasis, Am J Trop Med Hyg, 52, 427, 10.4269/ajtmh.1995.52.427